Inspire Medical Systems, Inc.

Freedom Capital Markets initiated coverage with a Buy rating and a $62 price target, signaling confidence that Inspire Medical can navigate its operational challenges stemming from the Inspire V launch and resume a growth trajectory, supported by a strong history of 46.8% annualized revenue growth over the past five years.

The troubled Inspire V device launch forced the company to slash its 2025 earnings guidance by over 80%, triggering a class action lawsuit and a downgrade by Evercore ISI to In-Line with a reduced price target of $40. Wall Street now projects an 8% revenue decline over the next 12 months, a stark reversal from prior growth rates.

With INSP trading at a P/E of 9.2x versus a peer average of 50.7x and an industry average of 24.5x, Simply Wall St estimates the stock is nearly 20% below its intrinsic fair value. Twelve analysts set a consensus 12-month price target of $52.17, representing over 24% upside from recent levels.

Despite the recent 49.8% stock price decline, Barchart analysts argue that INSP still trades at a demanding 49.8x forward P/E, reflecting significant optimism priced into the shares. Given the company's small scale of just $915.2 million in trailing revenue and weakening demand signals, better risk-reward opportunities exist elsewhere.

The global neuromodulation market is projected to grow from $10.91 billion in 2026 to $27.69 billion by 2035 at a CAGR of 10.9%, providing a substantial and expanding addressable market for Inspire Medical's hypoglossal nerve stimulation therapy as the category leader in sleep apnea treatment.

Despite a large market backdrop, Inspire Medical's Q1 2026 revenue grew only 1.6% as reimbursement friction materially constrained patient access and procedure volumes. This led management to cut full-year guidance by more than $100 million, demonstrating that macro market growth does not automatically translate into near-term commercial execution.